BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today reported that three abstracts addressing sub-study data from the company’s completed Phase 3 study of GATTEX™ (teduglutide) in patients with short bowel syndrome (SBS) were accepted for presentation at the 2009 Digestive Disease Week (DDW) conference. The DDW conference is being held from May 30 through June 4, 2009 at McCormick Place in Chicago, Illinois. The abstract titles and presentation times for two oral presentations and one poster presentation are summarized below.
